For Healthcare Professionals

Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies

clipboard-pencil

About the study

For dose escalation cohorts, the primary objective is to evaluate the safety and tolerability of REGN6569 as monotherapy lead-in and in combination with cemiplimab. For dose expansion cohorts, the co-primary objectives are: To assess the preliminary efficacy of REGN6569 in combination with cemiplimab, as measured by objective response rate (ORR) To assess the preliminary pharmacodynamic activity of REGN6569 as lead-in monotherapy, as measured by intratumoral Glucocorticoid-Induced Tumor necrosis factor receptor-Related (GITR)+ Treg depletion Secondary Objectives are: For dose escalation cohorts: To assess preliminary efficacy of REGN6569 in combination with cemiplimab, as measured by ORR, disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS) To characterize the pharmacokinetics (PK) of REGN6569 alone and in combination with cemiplimab To assess the immunogenicity of REGN6569 and cemiplimab For expansion cohorts: To characterize the safety profile in each expansion cohort To assess preliminary efficacy of REGN6569 in combination with cemiplimab, as measured by DCR, DOR, PFS, and OS To characterize the PK of REGN6569 alone and in combination with cemiplimab To assess the immunogenicity of REGN6569 and cemiplimab
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Key Inclusion Criteria:


  1. Dose escalation cohorts: Advanced stage (unresectable or metastatic) solid tumor malignancy, confirmed histologically or cytologically as defined in the protocol
  2. Dose expansion cohorts: Advanced stage (unresectable or metastatic) head and neck squamous cell carcinoma(HNSCC), confirmed histologically or cytologically as defined in the protocol

Mandatory biopsies: Able and willing to provide tumor tissue at baseline and while on treatment, with at least 1 soft tissue lesion amenable to biopsy by ultrasound or computed tomography (CT)-guided biopsy or under direct visualization


All Cohorts:


  1. Has no prior history of immune checkpoint blockade (ICB) therapy
  2. Has exhausted all approved available treatment options for their disease, with no other standard therapy likely to convey clinical benefit as defined in the protocol

EXCLUSION CRITERIA

Key Exclusion Criteria:


  1. Has previously received GITR-targeted therapy
  2. Has received any previous systemic biologic therapy within 5 half-lives of first dose of study therapy as defined in the protocol
  3. Has any condition that requires ongoing/continuous corticosteroid therapy (>10 mg prednisone/day or anti-inflammatory equivalent) within 14 days prior to the first dose of study therapy
  4. Has ongoing or recent (within 5 years) evidence of significant autoimmune disease that required treatment with systemic immunosuppressive treatments as defined in the protocol
  5. Has a known history of, or any evidence of, interstitial lung disease, or active, non-infectious pneumonitis in the past 5 years. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to first dose of study therapy
  6. Has uncontrolled infection with human immunodeficiency virus, hepatitis B or hepatitis C infection, or diagnosis of immunodeficiency
  7. Has received a live vaccine within 4 weeks of planned start of study medication. For dose escalation only: Has received a COVID-19 vaccination within 1 week of planned start of study medication or for which the planned COVID-19 vaccinations would not be completed 1 week prior to start of study.
  8. Has had prior allogeneic stem cell transplantation or received organ transplants at any time, or autologous stem cell transplantation

Note: Other protocol-defined Inclusion/ Exclusion criteria apply


pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

Squamous Cell Carcinoma of Head and Neck

Age (in years)

18+

Phase

Phase 1

Participants needed

85

Est. Completion Date

Jul 8, 2026

Treatment type

Interventional


Sponsor

Regeneron Pharmaceuticals

ClinicalTrials.gov identifier

NCT04465487

Study number

R6569-ONC-1933

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.